CASE STUDIES
Real World Impact
From use of our genomic data to validate a novel target for an early stage biotech to large scale retrospective clinical studies in support of multi-billion dollar drugs for top global pharmas, TriAxia provides the rare disease clinicio-genomic data our clients need
The model correctly predicted COPD-PH in 93.5% of patients analyzed
Global biopharma algorithm to detect COPD-PH patients
To enable recruitment for a Phase III trial, we developed an algorithm to detect undiagnosed patients with COPD-PH from generally available clinical data
Read Moreof US Patients achieved MCI
Global biopharma study of ‘Multi-Clinical Improvement’ (MCI) in US PAH patients as comparator to phase III Clinical Trial results
A top 5 global pharma needed data to support the Phase III trial of their latest blockbuster
Read Morerelevant genes differentially expressed in cases vs controls
Role of target pathway in disease pathophysiology for pre-clinical molecule
An early stage biotech had animal model data for a novel target and wanted to confirm with in-human genomics
Read More